Inflammation of the gastrointestinal tract is a complex biological response to harm caused by bacteria, damaged cells, or irritants. The symbiotic microbiome in the digestive tract is thought to protect the gut by eliminating unwanted stimuli and promoting recovery. The presence or lack of a microbiome can cause type 2 immunity to be worsened, as well as allergic/infectious and inflammatory consequences, including parasitic diseases. Inflammation of the gastrointestinal tract is frequently accompanied by changes in vascular anatomy and function. Microvascular congestion, Dilatation of the arteries supplying the tissue, and excessive fluid and protein leakage with interstitial oedema are examples of these disorders. IBD medications can often reduce inflammation and improve intestinal healing, leading in remission—long-term symptom relief. Many persons with IBD, however, have a chronic illness that requires lifelong therapy.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Complex endoscopy in pediatrics: Optimizing care
Monique Barakat, Stanford University School of Medicine, United States
Title : Use of indocyanine green fluorescence imaging in the extrahepatic biliary tract surgery
Orestis Ioannidis, Aristotle University of Thessaloniki, Greece
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States
Title : Efficacy of Sertraline on the symptoms and quality of life in patients with irritable bowel syndrome: A single-blinded and parallel designed randomized controlled trial
Sara Seifouri, St. Thomas NHS Foundation Trust, United Kingdom